4.7 Article

Second malignant neoplasms after treatment for Hodgkin's disease in childhood or adolescence

Journal

JOURNAL OF CLINICAL ONCOLOGY
Volume 18, Issue 7, Pages 1492-1499

Publisher

AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2000.18.7.1492

Keywords

-

Categories

Ask authors/readers for more resources

Purpose: To determine the frequency of and risk factors for second malignant neoplasms (SMNs) after treatment for Hodgkin's disease diagnosed in children and adolescents. Patients and Methods: One hundred eighty-two consecutive, previously untreated patients with Hodgkin's disease who were younger than 20 years of age at diagnosis and who were referred to Roswell Park Cancer Institute (Buffalo, NY) for treatment between January 1, 1960, and December 31, 1989, were studied, Sex-specific standardized incidence ratios (SIRs) were calculated. Kaplan-Meier survival estimates and Cox regression analyses were performed to determine the relationship of several demographic and treatment variables to SMN incidence. Results: Twenty-eight patients developed an SMN at a mean of 14.93 +/- 8.09 years (range, 2.65 to 29.88 years) after diagnosis of Hodgkin's disease. The cumulative percentage of patients who developed an SMN was 26.27 +/- 6.75% at 30 years after diagnosis, The SIR was 9.39 (95% confidence interval [Cl], 4.05 to 18.49) for male patients and 10.16 (95% Cl, 5.56 to 17.05) for female patients, The most frequent SMNs were thyroid cancer, breast cancer, nonmelanoma skin cancer, non-Hodgkin's lymphoma, and acute leukemia. Multivariate analysis of sex, treatment with any alkylating agent, treatment with doxorubicin, splenectomy, and relapse (as a time-dependent covariate) with time to SMN onset gave nonsignificant results. Conclusion: Successfully treated children and adolescents with Hodgkin's disease have a substantial risk for the occurrence of subsequent neoplasms, The most frequent SMNs (skint thyroid, and breast) ore readily detected by physical examination and available screening procedures. (C) 2000 by American Society of Clinical Oncology.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available